The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | The role of myeloma B-cells & pre-plasma cell progenitors in disease relapse following therapy
Rodger Tiedemann, MD, PhD, FRACP, FRCPA, Princess Margaret Cancer Centre, Toronto, Canada, shares some insights into a study which evaluated the role of myeloma B-cells and pre-plasma progenitor cells in disease relapse using whole exome sequencing (WES) and extensive mutational profiling. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen, AbbVie
